

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A polypeptide isolated isolatable from *H. medicinalis* having a molecular weight of about ~~12,000 +1 kD~~ 12,000 ± 1 kD with the biological activity of an inhibitor of collagen-dependent platelet adhesion, wherein said polypeptide binds to collagen thereby preventing the adhesion of platelets to collagen.

2. (Currently Amended) A polypeptide of claim 1 having an isoelectric point of pH ~~3.7 + 0.5~~ 3.7 ± 0.5.

3. (Currently Amended) A polypeptide of claim 1 having comprising six cysteine molecules ~~capable of forming~~ that form up to three -S-S- bridges.

4. (Currently Amended) A polypeptide of claim 1 which comprises ~~an the~~ amino acid sequences sequence of SEQ. ID. NO. 1 SEQ ID NO:1.

5. (Currently Amended) A polypeptide ~~comprising an amino acid sequence according to claim 4~~ which is at least 80% identical to the ~~amino acid sequence of SEQ. ID. NO. 1 over its entire length~~ polypeptide of claim 4.

6. (Withdrawn) An isolated polynucleotide encoding a polypeptide of claim 1.

7. (Withdrawn) An isolated polynucleotide comprising a DNA sequence of SEQ. ID. NO. 2, or a DNA sequence complementary to said DNA sequence wherein said polynucleotide is encoding a polypeptide of claim 1.

8. (Withdrawn) The polynucleotide of claim 7 wherein said polynucleotide comprises a DNA sequence that is at least 80% identical to that of SEQ ID NO: 1 over its entire length.

9. (Withdrawn) An expression vector comprising a DNA sequence of claim 6.

10. (Withdrawn) A host cell comprising the expression vector of claim 9.
11. (Withdrawn) An expression system comprising a host cell of claim 10.
12. (Withdrawn) A process for producing a polypeptide of claim 1 comprising a host which includes an expression vector with an isolated polynucleotide comprising a DNA sequence of SEQ. ID. NO. 2 culturing said host under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture supernatant or cell residue.
13. (Withdrawn) An antibody immunospecific for a polypeptide of claim 1.
14. (Previously Presented) A pharmaceutical formulation which comprises a polypeptide according to claim 1 and a pharmaceutical acceptable carrier or excipient therefore.
15. (Currently Amended) A pharmaceutical active agent of claim 14 for the treatment of a thromboembolic processes process.
16. (Currently Amended) A pharmaceutical formulation of claim 14 comprising an additional drugs ingredient wherein the additional drug ingredient is selected from aspirin, heparin or streptokinase or a combination thereof.
17. (Currently Amended) Use of a polypeptide according to claim 1 for the manufacture of a medicament for the treatment of thromboembolic diseases A medicament for the treatment of a thromboembolic disease comprising a polypeptide according to claim 1 and a pharmaceutically acceptable carrier.
18. (Withdrawn) Use of a polypeptide according to claim 1 for coating artifical surfaces.

19. (Withdrawn) Use of a polypeptide according to claim 1 for modifying intraocular lenses in order to lessen the thrombogenicity of the lens material.
20. (Withdrawn) Use of a polypeptide according to claim 1 for contacting the lens surface.
21. (Withdrawn) Use of a polypeptide according to claim 1 for covalent crosslinking to modify said lens material.
22. (Withdrawn) Use of antibodies according to claim 13 and a polypeptide isolated from *H. medicinalis* having a molecular weight of about 12 000  $\pm$  1kD with the biological activity of an inhibitor of collagen-dependent platelet adhesion to measure samples derived from a process for producing a polypeptide comprising a host which includes an expression vector with an isolated polynucleotide comprising a DNA sequence of SEQ. ID. NO. 2 culturing said host under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture supernatant or cell residue or a treated subject.
23. (Withdrawn) A method for identifying compounds which inhibit (antagonize) or agonize the polypeptide of claim 1 by observing the binding, or stimulation or inhibition of a functional response.
24. (Withdrawn) An agonist identified by the method of claim 23.
25. (Withdrawn) An antagonist identified by the method of claim 23.
26. (New) A polypeptide comprising the amino acid sequence of SEQ ID NO:1.